Literature DB >> 2079448

In-vitro and in-vivo activity of DR-3355, an optically active isomer of ofloxacin.

M Tanaka1, M Otsuki, T Une, T Nishino.   

Abstract

DR-3355 [S-(-)-ofloxacin], an optically active isomer of ofloxacin, showed a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria and was generally twice as potent as ofloxacin and considerably more active than DR-3354 [R-(+)-ofloxacin]. The activity of DR-3355 was largely unaffected by the type of culture medium, inoculum size and addition of human serum, but decreased under acidic condition at pH 6.0. The protective effect of orally administered DR-3355 in experimental infections in mice with various bacterial pathogens was superior to those of ofloxacin and ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2079448     DOI: 10.1093/jac/26.5.659

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens.

Authors:  S Yoshizumi; H Domon; S Miyazaki; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone.

Authors:  N Masuda; Y Takahashi; M Otsuki; E Ibuki; H Miyoshi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  In vitro activity of HSR-903, a new quinolone.

Authors:  Y Takahashi; N Masuda; M Otsuki; M Miki; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

5.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.

Authors:  B JI; N Lounis; C Truffot-Pernot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 9.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 10.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy.

Authors:  R Davis; H M Bryson
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.